Reinhard von Roemeling

Author

Also Known As

R Roemeling, R V Roemeling, R von Roemeling, R. Roemeling, R. V. Roemeling, R. Von Roemeling, R. von Roemeling, R.V. Roemeling, R.v. Roemeling, REINHARD VON ROEMELING

108

Publications

Citations

H-Index

Concepts

All Affiliations

Daiichi Sankyo (United States)Tennessee Oncology Arqule (United States)The University of Texas MD Anderson Cancer Center Curis (United States)

About

Reinhard von Roemeling is an author at Daiichi Sankyo (United States) specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	22	1.4K
2	Health Sciences	6	6	767
3	Public Health	1	1	34
4	Anesthesia	1	1	15
5	Applied Physiology	1	1	57

Reinhard von Roemeling

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Armando Santoro, Lorenza Rimassa, Ivan Borbath, The Lancet Oncology Second-line TreatmentPlacebo-controlled Phase 2OncologyHepatologyMedicine	2012	549
Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group Joachim von Pawel, Reinhard von Roemeling, U. Gatzemeier, Journal of Clinical Oncology	2000	285
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer Giorgio V. Scagliotti, Joachim von Pawel, Silvia Novello, Journal of Clinical Oncology	2015	256
Phase I Trial of Concurrent Tirapazamine, Cisplatin, and Radiotherapy in Patients With Advanced Head and Neck Cancer Danny Rischin, Lester Peters, Rodney J. Hicks, Journal of Clinical Oncology	2001	202
Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer Giorgio V. Scagliotti, Silvia Novello, Joan H. Schiller, Clinical Lung Cancer Non–small-cell Lung CancerOncologyMedicineLocally AdvancedPhase Iii	2012	126
Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. William J.M. Hrushesky, Reinhard von Roemeling, Rosellen Lanning, Journal of Clinical Oncology Surgical OncologyFudr Ia InfusionCircadian-shaped InfusionsPharmacotherapyTumor Biology	1990	118
Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial Robert C. Smallridge, John A. Copland, Marcia S. Brose, The Journal of Clinical Endocrinology & Metabolism	2013	112
Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. Reinhard von Roemeling, William J.M. Hrushesky Journal of Clinical Oncology Widespread CancerFudr InfusionPharmacotherapyMetronomic ChemotherapyOxidative Stress	1989	100
Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer Andres Forero‐Torres, Jeffrey R. Infante, David Waterhouse, Cancer Medicine	2013	90
Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study Ding‐Jen Lee, Andy Trotti, Sharon A. Spencer, International Journal of Radiation OncologyBiologyPhysics	1998	82

Page 1